Drugs / Baloxavir Marboxil tablets
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06507813 Comparator | Aug 2024 → Jan 2025 | influenza | Jiaxing AnDiCon Biotech Co.,Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Baloxavir Marboxil tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06507813 ↗ |
| Route | Oral | “Currently, there is only one treatment which only need one single oral dose for influenza in children five years above (Baloxavir marboxil) in China.” NCT06507813 ↗ |